Article

Optos ships next-generation imaging devices

Medical retinal imaging company Optos plc has delivered its first next-generation ultra-widefield retinal imaging devices (Daytona) to customers. The new devices have been scaled to accommodate smaller office spaces while providing high-resolution imaging and adding new autofluorescence capabilities.

London-Medical retinal imaging company Optos plc has delivered its first next-generation ultra-widefield retinal imaging devices (Daytona) to customers. The new devices have been scaled to accommodate smaller office spaces while providing high-resolution imaging and adding new autofluorescence capabilities.

According to Optos, the devices feature a new, ergonomic body designed to increase patient comfort as well as make it easier to position the eye correctly; an improved user interface with an intuitive, workflow-based software; “plug-and-play” installation; image review capabilities; and electronic image storage options. The device was designed to allow the globalization of the company’s core imaging technology.

“We are pleased to announce shipment of our first devices on schedule,” said Roy Davis, chief executive officer, Optos plc. “Following the unveiling of [the next-generation devices] in October, we have seen growing demand for the product, and over the coming months we will be increasing our manufacturing capacity accordingly. We believe [these devices] represent an excellent growth opportunity for Optos.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.